Wall Street Zen Downgrades ICU Medical (NASDAQ:ICUI) to Hold

ICU Medical (NASDAQ:ICUI) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other research analysts have also recently commented on the company. KeyCorp upped their target price on ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd. Finally, Piper Sandler upped their price objective on ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, ICU Medical currently has a consensus rating of “Moderate Buy” and an average target price of $175.67.

ICU Medical Trading Up 3.0%

ICUI stock opened at $154.16 on Friday. The company has a quick ratio of 1.19, a current ratio of 2.45 and a debt-to-equity ratio of 0.62. ICU Medical has a twelve month low of $107.00 and a twelve month high of $165.17. The stock has a market capitalization of $3.81 billion, a price-to-earnings ratio of -497.27 and a beta of 0.79. The firm’s fifty day simple moving average is $148.59 and its two-hundred day simple moving average is $134.50.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.60. The firm had revenue of $533.30 million during the quarter, compared to analyst estimates of $511.46 million. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The business’s revenue was down 8.9% on a year-over-year basis. During the same quarter last year, the business earned $1.59 EPS. As a group, analysts anticipate that ICU Medical will post 4.11 earnings per share for the current year.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, Director Elisha W. Finney sold 1,285 shares of ICU Medical stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total transaction of $180,439.70. Following the completion of the sale, the director directly owned 3,995 shares of the company’s stock, valued at $560,977.90. The trade was a 24.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Virginia Ruth Sanzone sold 930 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total value of $132,376.20. Following the transaction, the vice president directly owned 5,456 shares in the company, valued at $776,607.04. The trade was a 14.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Arizona State Retirement System lifted its position in shares of ICU Medical by 1.3% in the 3rd quarter. Arizona State Retirement System now owns 6,903 shares of the medical instruments supplier’s stock worth $828,000 after purchasing an additional 91 shares during the period. Oregon Public Employees Retirement Fund raised its stake in ICU Medical by 1.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,631 shares of the medical instruments supplier’s stock worth $803,000 after buying an additional 100 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in ICU Medical by 11.6% during the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after buying an additional 101 shares during the period. BNP Paribas Financial Markets boosted its position in ICU Medical by 4.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,459 shares of the medical instruments supplier’s stock valued at $325,000 after acquiring an additional 107 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its position in ICU Medical by 0.6% during the 2nd quarter. Thrivent Financial for Lutherans now owns 18,098 shares of the medical instruments supplier’s stock valued at $2,392,000 after acquiring an additional 114 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.